BDSX vs. XGN, EUDA, SERA, QIPT, NAKA, KDLY, ATPC, CORBF, OPGN, and PIII
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), Global Cord Blood (CORBF), OpGen (OPGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.
Biodesix vs. Its Competitors
Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 30.1% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Exagen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled Biodesix'saverage media sentiment score.
Exagen presently has a consensus target price of $7.50, suggesting a potential upside of 7.14%. Biodesix has a consensus target price of $1.75, suggesting a potential upside of 473.02%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Exagen.
Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
Exagen has a net margin of -27.34% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -133.69% beat Biodesix's return on equity.
Summary
Exagen beats Biodesix on 9 of the 14 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 7/10/2025 by MarketBeat.com Staff
Free BDSX Stock Alerts